Effects of the Japanese Kampo Medicines Rikkunshito, Shakuyakukanzoto and Goreisan on Lenvatinib Plasma Concentrations in Japanese Patients with Thyroid Cancer.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: thyroid cancer
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] Although these Kampo medicines are reported to inhibit drug-metabolizing enzymes and drug transporters, the risk of drug interactions for patients receiving lenvatinib therapy is low. Patients should feel confident that they can receive Kampo medicines as supportive care for lenvatinib therapy without a risk of drug interactions that could affect treatment efficacy.
[BACKGROUND] Kampo medicines are often used in Japan as therapy for the side effects induced by oral kinase inhibitors.
- 표본수 (n) 21
- p-value P = 0.007
- p-value P = 0.029
APA
Fujita K, Suzuki A, et al. (2025). Effects of the Japanese Kampo Medicines Rikkunshito, Shakuyakukanzoto and Goreisan on Lenvatinib Plasma Concentrations in Japanese Patients with Thyroid Cancer.. Drugs - real world outcomes, 12(1), 153-160. https://doi.org/10.1007/s40801-024-00467-6
MLA
Fujita K, et al.. "Effects of the Japanese Kampo Medicines Rikkunshito, Shakuyakukanzoto and Goreisan on Lenvatinib Plasma Concentrations in Japanese Patients with Thyroid Cancer.." Drugs - real world outcomes, vol. 12, no. 1, 2025, pp. 153-160.
PMID
39616563
Abstract
[BACKGROUND] Kampo medicines are often used in Japan as therapy for the side effects induced by oral kinase inhibitors. However, the pharmacokinetic interactions between Kampo medicines and oral kinase inhibitors such as lenvatinib have not been studied.
[OBJECTIVE] We investigated the effects of Kampo medicines (rikkunshito, shakuyakukanzoto and goreisan) on the steady-state plasma trough concentration (C) of lenvatinib in patients with thyroid cancer.
[METHODS] Thirty-nine patients receiving lenvatinib therapy at Ito Hospital between May 2015 and December 2019 were enrolled. The mean C of lenvatinib with Kampo medicine, at the same dose as before initiating Kampo medicines, was used.
[RESULTS] After the repeated administration of rikkunshito (n = 21), shakuyakukanzoto (n = 10) or goreisan (n = 8), the mean C of lenvatinib and the laboratory test values of patients did not change significantly. In contrast to rikkunshito, which alleviates emesis by enhancing gastric emptying, the C values of lenvatinib with a proton pump inhibitor (PPI) (n = 16) or histamine H receptor antagonist (H2RA) (n = 4) were significantly lower than the C values without a PPI or H2RA (P = 0.007). The mean (range) change rate of the C of lenvatinib with a PPI or H2RA versus without a PPI or H2RA was 88.6% (69.9-115%), and was significantly greater than the change rate for rikkunshito (P = 0.029). There was no significant difference between the C of lenvatinib with a prokinetic agent (n = 7) versus without a prokinetic agent (P = 0.365).
[CONCLUSIONS] Although these Kampo medicines are reported to inhibit drug-metabolizing enzymes and drug transporters, the risk of drug interactions for patients receiving lenvatinib therapy is low. Patients should feel confident that they can receive Kampo medicines as supportive care for lenvatinib therapy without a risk of drug interactions that could affect treatment efficacy.
[OBJECTIVE] We investigated the effects of Kampo medicines (rikkunshito, shakuyakukanzoto and goreisan) on the steady-state plasma trough concentration (C) of lenvatinib in patients with thyroid cancer.
[METHODS] Thirty-nine patients receiving lenvatinib therapy at Ito Hospital between May 2015 and December 2019 were enrolled. The mean C of lenvatinib with Kampo medicine, at the same dose as before initiating Kampo medicines, was used.
[RESULTS] After the repeated administration of rikkunshito (n = 21), shakuyakukanzoto (n = 10) or goreisan (n = 8), the mean C of lenvatinib and the laboratory test values of patients did not change significantly. In contrast to rikkunshito, which alleviates emesis by enhancing gastric emptying, the C values of lenvatinib with a proton pump inhibitor (PPI) (n = 16) or histamine H receptor antagonist (H2RA) (n = 4) were significantly lower than the C values without a PPI or H2RA (P = 0.007). The mean (range) change rate of the C of lenvatinib with a PPI or H2RA versus without a PPI or H2RA was 88.6% (69.9-115%), and was significantly greater than the change rate for rikkunshito (P = 0.029). There was no significant difference between the C of lenvatinib with a prokinetic agent (n = 7) versus without a prokinetic agent (P = 0.365).
[CONCLUSIONS] Although these Kampo medicines are reported to inhibit drug-metabolizing enzymes and drug transporters, the risk of drug interactions for patients receiving lenvatinib therapy is low. Patients should feel confident that they can receive Kampo medicines as supportive care for lenvatinib therapy without a risk of drug interactions that could affect treatment efficacy.
같은 제1저자의 인용 많은 논문 (5)
- The Clinical Impact of Cardiovascular Thrombosis on Overall Survival in Patients With Hepatocellular Carcinoma After Transarterial Chemoembolization.
- ASO Author Reflections: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness.
- ASO Visual Abstract: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1.
- Real-world outcome and dose intensity of Pola-R-CHP versus R-CHOP/R-THP-COP in newly diagnosed diffuse large B-cell lymphoma: a single-center, retrospective cohort study.
- High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1.